Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Zai Lab Limited < Previous 1 2 Next > Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China September 18, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China August 30, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Participation in September Investor Conferences August 29, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates August 07, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023 July 20, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients July 19, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy July 17, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ARGX ZLAB Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer July 14, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis July 10, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer July 06, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China June 30, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ARGX ZLAB Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA June 28, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies June 06, 2023 From Zai Lab Limited Via GlobeNewswire Tickers NVCR ZLAB Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting June 01, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Participation in June Investor Conferences May 25, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA May 18, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates May 09, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology April 27, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023 April 20, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting April 11, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia March 20, 2023 From Zai Lab Limited Via GlobeNewswire Tickers KRTX ZLAB Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates March 01, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Participation in March Investor Conferences February 28, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress February 22, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA February 22, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023 February 09, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Participation in February Investor Conferences January 31, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA January 30, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List January 18, 2023 From Zai Lab Limited Via GlobeNewswire Tickers ZLAB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.